Effective targeting of primary human acute myeloid leukemia using anti-CD123 chimeric antigen receptor engineered T cells

      Most patients with AML are incurable. We recently reported on immunotherapy with anti-CD19 chimeric antigen receptor transduced autologous T cells (CART-19) in patients with CLL. Successful CART cell therapy relies on a suitable cell-surface target; identifying an AML-specific surface antigen is challenging as many antigens are shared between normal myeloid progenitors and AML blasts. We found CD123 to be the most frequently and highly expressed target among 26 AML specimens. Furthermore, CD123 was more highly expressed on AML blasts than on normal marrow cells.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect